A phase 3 randomized, controlled, open-label, multicenter, safety and efficacy study of dexamethasone plus MLN9708 or physician's choice of treatment administered to patients with relapsed or refracto
09/28/2012 - 09/27/2021 (PI)Millennium Pharmaceuticals, Inc.
A Phase I/II Trial of Pomalidomide and Dexamethasone for the treatment of patients with AL Amyloidosis
03/01/2012 - 02/28/2021 (PI)Celgene Corporation
Molecular Imaging of Primary Amyloid Cardiomyopathy
04/01/2017 - 03/31/2020 (Co-Investigator)The Brigham and Women's Hospital, Inc. NIH NHLBI5R01HL130563-04
A Phase I Dose-Escalation Study of Carflizomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
12/12/2013 - 12/12/2019 (PI)Academic Myeloma Consortium
Phase II study of the combination Bendamustine and Dexamethasone in patients with relapsed AL amyloidosis
09/04/2012 - 09/09/2019 (Subcontract PI)Trustees Of Columbia University In The City Of New York Cephalon, Inc
A phase 1, open label, dose escalation study of intravenous administration of single agent NEOD001 in subjects with light chain (AL) amyloidosis
05/08/2013 - 05/07/2019 (PI)Onclave Therapeutics Limited
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients with Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further
04/01/2011 - 03/03/2019 (PI)Millennium Pharmaceuticals, Inc.
A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of
01/06/2016 - 01/05/2019 (Co-Investigator)Fred Hutchinson Cancer Research Center Scleroderma Res Fdn
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 PLus Lenalidomide and Dexamethasone versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagno
12/03/2013 - 12/02/2015 (PI)Millennium Pharmaceuticals, Inc.
Phase II trial of induction therapy with Bortezomib and Dexamethasone followed by high-dose melphalan and stem cell transplantation in patients with AL amyloidosis
04/01/2009 - 01/25/2014 (PI)Millennium Pharmaceuticals, Inc.
Showing 10 of 14 results.
Show All Results
STI-6129-001: A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Systemic AL Amyloidosis
12/01/2020 - 11/30/2023 (PI)Sorrento Therapeutics, Inc.
A Phase II randomized single-blind study to evaluate the activity and safety of low dose oral…
04/23/2020 - 04/22/2023 (PI)Karyopharm Therapeutics Inc.
DFCI 19-291: A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone…
12/23/2019 - 12/22/2022 (PI)Dana Farber Millennium Pharmaceu
Oncopeptides: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL…
11/21/2019 - 11/20/2022 (PI)Oncopeptides AB
04/15/2019 - 04/15/2022 (PI)Janssen Scientific Affairs LLC
DARA/JANSSEN PI Initiated
03/28/2017 - 03/28/2021 (PI)Janssen Scientific Affairs LLC
11/17/2017 - 11/17/2020 (PI)Janssen Research and Development, LLC
09/24/2015 - 09/30/2019 (PI)Prothena Therapeutics Limited
PRONTO - Protocol NEOD001-201
05/13/2016 - 03/31/2019 (PI)Prothena Therapeutics Limited
Phase 1 Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL …
05/11/2015 - 03/31/2019 (PI)Karmanos Cancer Center
Showing 10 of 11 results.
Show All Results